Kringle Pharma, Inc. (4884.T)
Tokyo · JPY · Healthcare · Biotechnology
¥605 (+7.07%) as of
Key statistics
- Market cap
- 4.89B
- EPS (TTM)
- -104.12
- Dividend yield
- 0.00%
- 52-week range
- 287.00 – 741.00
- Beta
- 0.38
- Revenue (TTM)
- 342.21M
- Profit margin
- -236.24%
- Volume
- 76.30k
About Kringle Pharma, Inc.
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Kita, Japan
- Employees
- 17
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.